baricitinib plus remdesivir - versus remdesivir - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.65 [0.39, 1.09]< 10%1 study (1/-)95.0 %lownot evaluable highcrucial-
deaths (time to event analysis only) 0.65 [0.39, 1.09]< 10%1 study (1/-)95.0 %lownot evaluable highcrucial-
clinical improvement 1.16 [1.01, 1.33]> 10%1 study (1/-)98.5 %lownot evaluable highimportant-
clinical improvement (14-day) 1.30 [1.03, 1.64]> 10%1 study (1/-)98.6 %lownot evaluable highimportant-
death or ventilation 0.69 [0.50, 0.95]< 10%1 study (1/-)98.8 %lownot evaluable highimportant-
time to recovery 1.16 [1.01, 1.33]> 10%1 study (1/-)98.5 %lownot evaluable highnon important-

safety endpoints 00

superinfection 0.50 [0.32, 0.79]< 10%1 study (1/-)99.8 %lownot evaluable highimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.